shares of biotech company regeneron are lower. regeneron's partner sanafy about a cholesterol drug the companies are co-developing. both companies say they are unaware of any adverse effects. they are being asked by the fda to take a closer look and do some more testing on possible effects. sue? >> yikes. a loss of 7.33% today. >>> the rest of the markets, let's get you up to date. fuel cell energy, the battery makers we told you about earlier, with significant gains. there's another look at regeneron. now let's take a look at the markets. up 13 points on the dow jones industrial average. the s&p 500 down less than .1%, 1 1/2 points. the nasdaq is off half a percent or almost 23 points. almost exactly 23 points. three winners now, vf corp, mellon and financial prudential, with gains of at least 2%. that does it, right? >> going up to 50 this weekend. 50 is the new 70. that will do it for "power lunch." >> have a great weekend, everybody. see you on monday. "street signs" begins right now. >>> well, it has now been five years since

regeneron, what is it and why do you like it. >> absolutely. launched a new drug for age related macular degeneration which is ocular drug. it has done fantastically well. the stock is up 20 fold. david: ocular meaning what? >> injectible drug for the eye? david: for glaucoma, things like that. >> age related macular degeneration the leading cause of loss of vision for elderly. their guidance is 1.to 1.billion dollars. we're seeing label expansion into new areas like diabetic blindness. david: they have all the patents? you don't have to worry about that. >> patents are in fantastic shape. that is one thing really attractive by the biotech space and these kind of drugs. they're partnered with bayer overseas. this is revery, very lucrative partnership. for example, bayer did $200 million in sales. ilia will be 2 billion-dollar drug overseas. drop 6 to $700 million. david: partnership with bayer takes me back to the original question. i wonder if the big pharmas don't come in and say, hey, i can do that? >> m&a is always a foundation to valuation

intermune and regeneron. what do you make of this? is in a bubble but it has been a word thrown out there. is biotech an area you are at all interested in investing in? >> you really have to knowç th space. i think it's like computer security. you got to really be an expert in that. i think you are right, you got to get in very early. biotech is one of those things when it's obvious that the stock is doing well, it's probably too late. >> absolutely. >> except if it got that next -- that's the thing. they trade on these trials, then hopefully they come to market and probably sell out to a bristol myers or merck. the biotechs -- >> in that market it's really distribution. once you get beyond a certain size, there are very few companies that have the scale to distribute the product. >> to mandy's point, it's been so hot. almost every name is soaring. everything is green, green, green. >> people are getting old. people are getting sick. >> the drugs can be $80,000 a year. if you're not covered by insurance, you are done. >> obama care.

regeneron is up 20 mkt.valuations are a concern here, all of these stocks have nearly doubled in value over the course of the past 12 months, alexion, a plain and simple, investors may be taking some profits. mandy? >> dom, thank you very much. >>> a little bit of background there. whether or not we should be concerned about this, what do you think, carter? >> mandy, some of the actions, here is the set-up, of course, we know how well biotech has performed relative to the s&p. it's five fold increase over the last ten years. with that setup, here's the biotech index. it keeps going over and over bouncing off its well-defined trend line. the leading four stocks in the group, celgene has bounced and bounced. now it's starting to falter. which is to say it's broken below its trend line. that's how trouble starts. one starts, then the next. here's celgene versus the biotech index. you're seeing this as a divergence between celgene and its own group. we have the break in the trend. we have a minor head and should

regeneron is up 20%. biogen up around that same amount. now, valuations are a concern here, all of these stocks have nearly doubled in value over the course of the past 12 months, alexoin trades at 138 times earnings. plain and simple, investors may be taking some profits. that's why you may be seeing weakness this time around. mandy? >> dom, thank you very much. >>> a little bit of background there. now we need to know whether or not we should be concerned about this, what do you think, carter? >> mandy, some of the actions, is concerning. let's try to figure it out today. here is the set-up, of course, we know how well biotech has performed relative to the s&p. it's five fold increase over the last ten years. with that setup, here's the biotech index. the s&p the official. and what we know is it keeps over and over and over bounces off its well-defined trend line of the past year. but now take a look at one of the leading four stocks in the group. celgene has bounced and bounced. now it's starting to falter. which is to say it's broken b

citi group goes hold the bite on regeneron.they early with the stock at 180 last year. >> how can you be early when the sto stock's up 100% over a year. >> one of my favorite ceos. i think citi should have moved earlier. like coming in and saying i've had a hard look at florida, i think they should be number one seed. no, they are number one seed. where have you been? where have you been? it's not syracuse, which i thought was going to be number one a month ago. be careful. the stock up last week. regeneron, not fallen. we've got another three biotech offering this week. all going to generate excitement. be careful, froth biotech. >> love the kornheiser bandwagon. >> good old days in d.c. "squawk on the street" going to be right back from post 9. ♪ [ girl ] my mom, she makes underwater fans that are powered by the moon. ♪ she can print amazing things, right from her computer. [ whirring ] [ train whistle blows ] she makes trains that are friends with trees. ♪ my mom works at ge. ♪ my mom works at ge. predibut, manufacturings a

but i think companies like celg, very strong fundamentals, regeneron, and i add lower risk, lower multiple pharmaceutical companies like pfizer, like a merck, and some of distributors look a cardinal health or express scripts. >> are there any sectors of biotech -- you named companies, we appreciate that -- that you feel are particularly at risk here? given the waxman letter about gilead? >> absolutely. this is just punctuates the point that investors always have about the sustainability of pricing. and i think at the end of the day, it's still going to be a free market. and the best way to price is to innovate. and we are seeing a lot of innovation. i think this scare, if you will just puts some balance in the equation. we've seen multiples come down. and that correction is probably healthy and should happen. but i think the tone going forward will still be driven by strong fundamentals. >> what dow you in will happen to the biotech sector from here, matt. >> well, it could see a little bit more weakness. even before gilead got the letter from the congressman on friday, the group was alre

ring the register you want to play on eye medicine, regeneron is probably not done.ust saying, that's a better company. now your tweets. okay. we've got to get to some of the tweets you have been sending in because they're stockpiling and i have been negligent. all right. let's take a tweet from physical cliff who says, you make my day, love what you do for people, skee-daddy. a big canadian booyah for all you do. well, i tell you i needed this one because i'm just completely blasted. so i'm trying very hard to do the show. i'm a perfect attendance guy. i don't want to give up, but this made me feel good. typically on a day when i was not able to talk for most of it. all right. let's be to scott who says, kudlow and cramer brought back great memories. congrats, larry. yeah, i mean, i forgot how much fun that show was and when i looked at that picture of me and larry when we did the coin flip, i said, oh, man. i have lost 25 pounds. so let's do -- why don't we go to pete -- take a tweet from @petecrown42 who says talk to me about merck, jim. booyah from ohio. i think

i tend -- david: what about the ones he mentioned, novavax and gilead and regeneron? don't follow the stocks specifically. as we see some bounces maybe you will differentiate the potentially the good from the bad. one other thing i'll add. going back last five years, biotech, the best month of year for biotech has been march. it has been up every march for five years. when you see weakness in best month you see -- cheryl: that is bull-bear debate. gentlemen, thank you very much. david: thanks a lot, guys. bitcoin investors hoping that the irs might give them a pass. well they have to think again. irs announcing brand new rules for the digital currency today. if you gained or lost on bitcoin, you better listen up to this. cheryl: and the beer industry, seeking to get some buzz from a couple of the most popular tv series ever. yes, television. we'll tell you how when we go "off the desk." (announcer) scottrade knows our clients trade and invest their own way. with scottrade's smart text, i can quickly understand my charts, and spend more time trading. their quick trade

that's not because high-quality biotech companies like celgene, regeneron have gone bad.ng has changed at the companies. the stocks are out of favor thanks to this rotation. as i said at the top of the show, the hedge funds and high-growth mutual fund playbook says you should sell these guys when the federal reserve says the economy's heating up. so tonight i want to show you what this rotation looks like from another angle. that's right. we're going to go off the charts to see exactly what's happening to the biotechs here. we're going to use the help of bob lang, a brilliant chartist who is the technical star behind the trifecta stock's news letter at the street.com as well as founder and senior strategist at explosiveoptions.net and a guy whose work i analyze in "get rich carefully." take a look at this chart of the ishares, the ibv. this is a terrific chart of tracking the etf of tracking the larger capitalization of biotechs. it's just -- in just the last month, this thing has dropped $34. 12.4%. over the last few days in particular, the biotech etf has been obliterat

now since we've seen the biotech names like regeneron, they're saying maybe we lock in gains and that'shat we've seen in the past month. the question here is is this a rotation that will last or are we seeing money allocates? sfl we went out to the jpmorgan health care conference in january and we found companies that were god, od, that maybe w not going to go on tv but agios pharmaceutical was a name. it's up 140% this year. agios up 90% this year. but it is important to remember, as you know, me liz is a, a lot of these names are binary outcomes. the brug works, great, worth billions. or it fails. there's your risk. >>> coming up, spring has sprung. and diana olick keeping track of whether the spring housing selling season is going to really spring off. more "half time report" coming more "half time report" coming up next. pretty difficult thing to do. >>> welcome back. guess what, we have a big media deal today. media general buying lynn media for $763 million and 45 1/2 million shares of stock. the approximate per share value, let's leave that to dominic chu. what have you got? >> o

here's a group that had been dominated by amgen, cellgene and regeneron.the most important leadership group in the market thanks to a number of big drug approvals. and some super mergers that seem to be happening pretty much once a month. the biotechs were able to snap back today and while the approvals are occurring, the biggest so far seems below forecast and that's crimping the whole group, although the stock bounced back well today and the group is up huge year-over-year. given the size of the number of people with hep-c and the life-saving agent of the drug, i don't know why there are fears. each week, they seem to get worse. number of new biotech ipos has been overwhelming. many left for dead biotechs that were the equivalent of penny stocks are sucking money out of the big boys. i wish i could say it was justified, but it's usually a sign of speculation. let's not forget that the biotechs always, always, always underperform. and that's exactly what people think we're having right now. aerospace, cloud and biotech all have issues that cannot be solve

regeneron pharmaceuticals is a winner on potential launch of its drug in japan.ou guys. >> thank you very much. let's go to dominic chu. >>> check out what's happening with magna international. the auto parts manufacture is posting better than expected fourth quarter profits. it announced a 19% increase in its dividend. you can see the shares up about 4.5% to 5%. tyler? >> thank you very much. sell-off today but historically, march has been a pretty good month for stocks. should investors follow buffett's advice and get in or is it time to stay the heck away? we'll tackle that when we come back. tdd# 1-888-628-2419 searching for trade ideas that spark your curiosity tdd# 1-888-628-2419 can take you in many directions. tdd# 1-888-628-2419 you read this. watch that. tdd# 1-888-628-2419 you look for what's next. tdd# 1-888-628-2419 at schwab, we can help turn inspiration into action tdd# 1-888-628-2419 boost your trading iq with the help of tdd# 1-888-628-2419 our live online workshops tdd# 1-888-628-2419 like identifying market trends. tdd# 1-888-628-2419 now, earn

other players in the field are sanofi in collaboration with regeneron and pfizer. >> we nouknow a lotnies move in terms of their share price on hope. if you take a statit, n, it can a pill, but some of these new drugs can be very expensive and might be injectable. >> absolutely. so they will be injectable, although they can be self injected. they will be every several weeks or even once a month, and because they're bye-b biologics they will be very expensive. lipitor was the large esst sell drug in the world. additional, it is still not clear whether the measurements of cholesterol are going to be sufficient for regulators and specifically the fda to approve these drugs. so right now there are long-term studies to measure whether those reductions in ldl translate into benefits in terms of card cardiovascular disease, lower incidents of risk. that data will not be available before 2018. >> macro sense, biotech has been a hot story. everybody freaking out about this gilead sciences payment news. did people overreact to gilead or was the sell-off deserved and overdo? >> nothing goes stra

all the names we've been talking about a lot over the last year, gilead, alexion, and regeneron taking a big hit. and the reason, a letter from congressional democrats to gilead abouting about the new drug to treat hep "c." the big concern, pricing. it can cost up to $1,000 a day, which means $84,000 for a three-month treatment. so very, very expensive. and there is no government regulation of drug pricing. medicaid and medicare can negotiate discounts, but this letter sparked a lot of concern that the government can now start to intervene and bring down some of the big, big prices of some of these new super drugs. most analysts are not concerned about this case specifically. there's a lot of clinical data that shows support that all of these pricey drugs have better cure rates, but there has been some biotech buying and selling going on after the sharp drop-off. you can see that the session did bounce back from session lows. and this is a sector is up. so today's move is a relatively small one. but completely adds fuel to the fire that the biotech party could be coming to an end soon.

the one lone winner we have here at the nasdaq today is actually a biotech name, regeneron pharmaceuticalsany said it was coming out for a new diabetes drug so that is a spot of green that we are seeing today. but again, very few, very far between. investors clearly in that mentality. tech taking the brunt of it. >>> guys, quickly, what caught my eye, you have this big down day, tesla stock is barely down. the stock doesn't want to go down. >> i think people look at that as well, gee, if the market turns that's going to be a leader, so i better not get out of it. >> certainly if you were going to sell stocks today, given that stock's run, that would be one at the top of your list to take profits. >> easier to sell something as big as an apple, though. the bigger, the better when you want to get liquid, you can get l liquid really quickly. >> pete najarian was buying nokia based on unusual activity last week. the stock under pressure today, down more than 3%. what name will you get into now? >> they have rallied back a little off that push to the down side. those were may 8 calls somebody r

same thing goes for celgene, regeneron, the four horse men of the pharma. they are not stopped by a second crimea war, neither are the combatants that have created the incredible drugs to try to stop them. then there's the oil and gas revolution that we've focused on for ages. could this be damaged by the incursion into ukraine? hardly. benefit from tensions between russia and western europe. they benefit. consider the company we have on tonight. wow, did you see it today? continental resources. the biggest landowner in the bakken shale in north dakota. here's a company that directly benefits from turmoil that could restrict energy exports from russia, driving up the price of crude worldwide. it know it seems a little illogical given that continental's crude goes to gasoline in this country. remember gasoline in this country is priced off the inflated oil price set in europe, not by the domestic price here. and that means bakken oil is even more valuable to east coast refineries than ever because of what was happening with ukrainian/russian tensions. contin

stocks like regeneron or salesforce.com. these all got hammered. these companies put up tremendous sales growth through thick and thin. we're in thick mode now after this employment number. we' where a whole bunch of stocks can show accelerating revenue growth. that's what the market wants after a strong employment number. rotation, people. now, nothing's ever crystal clear with the stock market. so much happens ahead of the important data that we focus on. many of the industrials had already rallied mightily into this number as the employment bulls placed gobs of money into these stocks moving them up in advance, betting that a strong labor report means really good earnings reports down the road. when they did get it right, some of the bulls rang the register at the opening. because the gains between 9:30 and 10:00 for these stocks were outsized. others were distressed that interest rates did go up as they always do when economic data comes in stronger than expected. so some stocks were hurt convinced higher rates will slow down the growth of the

it's alexian, biogen, amgen, regeneron, they're all down on the day but off their session lows. one headline that's drawing all the shares and gilead comes by congress, congressional democrats asked to be briefed by the company on its hepatitis "c" drug and the costs that come with it. it was a reason for traders to hit the sell button on those biotech stocks. let's put it in perspective here. this industry group in the s&p 500 was up 46% over the past year entering today. now the etf is down 8% from its highs on february 25th. this could just simple i be profit taking. that's what some traders are saying. that's what cowen's head of equity trading thinks. he's not getting the sense this is a larger rotation at all out of biotech stocks. he does say if some big rotation out of biotech were to happen, even his 11-year-old kid would know about it. some price action to the downside. nothing concerning a lot of traders just yet. >> thank you, tom. tonight at 5:00 eastern, "fast money" is talking more biotechs, because jim cramer has the ceo of biogen on and that will be a great conv

biotech continues to trade under pressure, celgene, gilead, regeneron pharmaceuticals lower on the day's resulted in the nasdaq biotech index underperforming the major indexes, down on the day. i also want to point your attention to some of the old school tech names. talking about oracle among others, seeing this rotation into old school tech. cantor fitzgerald initiated coverage with a buy rating, indicating their engineered systems could be a quote, game changer in the i.t. world. analysts also writing that profit growth looks attractive, seeing shares of oracle higher on the day. lastly, blackberry. in focus, of course, posting a smaller than expected loss thanks to lower expenses. its ceo john chen spoke about its turn-around strategy. shares were up as much as 3% but now lower by around 2% on the day. back to you. >> thank you very much, seema. appreciate it. >>> the metals markets closing for the week momentarily. it's been a very volatile week. comex gold down $1.30. rebound in the silver market. copper, this is the second day running we have had a large percentage move to the u

bioengineered proteins that keep your liver from absorbing cholesterol and companies like amgen, sanafi, regeneronand pfizer are working on these kind of drugs. here's a catch. statins are typically pills taken orally, they are cheaper because generic versions are available and these new versions are meant to be taken as injections periodically. they could cost a heck of a lot more as well. there is also more testing that needs to be done but investors seem to be optimistic at least for now. check out shares of amgen. they are outperforming the market today. could be one of the reasons why this news on perhaps a new beneficial form of combatting high cholesterol. tyler? >> dominic chu, thank you very much. >>> open enrollment for obamacare comes to an end. yes, we really mean it, an end today. did the people who were supposed to do it, do it and is this going to be a big win or a big loss for the obama legacy? dan mangun of cnbc.com is here. we will get to you in just a minute. meanwhile, bertha coombs and that last minute rush to sign up. it has been quite a number of people. >> it really has bee

>> our favorite large caps would be cellgeny, alexion, regeneron. absolutely. >> appreciate it.u. >> thanks, joe. >>> kermit the frog and company had a rough weekend at the box office. >>> big news from bmw. this is a surprise, actually. phil lebeau at south carolina at its assembly factory, a closer look at why the german automaker is expanding in the u.s. and not in its home country. we'll be back with that story and a lot more. so our business can be on at&t's network for $175 a month? yup. all 5 of you for $175. our clients need a lot of attention. there's unlimited talk and text. we're working deals all day. you get 10 gigabytes of data to share. what about expansion potential? add a line, anytime, for $15 a month. low dues, great terms. let's close! new at&t mobile share value plans our best value plans ever for business. >>> welcome back to "squawk box," everybody. the movie "divergent" dominating the weekend box office earning $56 million, the second highest opening so far this year. 300 rise of an empire holds that title. as for the "muppets most wanted" landed in secon

in fact, i was talking to the folks at regeneron. they're looking -- it's a biotech company.cal build experience. there are hundreds of jobs available. those two companies combined have 1,000 opportunities. it's getting people to these job fairs and helping them get that resume together. >> that's right. it's not quite 9:00 o'clock here in new york city. maybe thousands by the end of the day there. cheryl casone, thank you very much for joining us live. >> more "fox & friends" in just a moment ♪ they lived ♪ they lived. ♪ they lived. ♪ (dad) we lived... thanks to our subaru. ♪ (announcer) love. it's what mas a subaru, a subaru. ♪ ♪ ♪ great. this is the last thing i need.) seriously? let's take this puppy over to midas and get you some of the good 'ol midas touch. hey you know what? i'll drive! i really didn't think this through. brakes, tires, oil, everything. (whistling) ...of america's number-one puppy food brand... ...with dha and essential nutrients also found in mother's milk. purina puppy chow. >>> tomorrow we're going to be back here, the governor of indiana will be dr